Mandate

Vinge advises international private equity firm Cinven on the acquisition of Envirotainer

July 12, 2018 M&A

Headquartered in Stockholm, Envirotainer designs, manufactures and leases active temperature-controlled containers used primarily for air freighting biopharma products, transporting up to two millions doses of medicine per day. Envirotainer serves c. 600 customers worldwide, including many of the blue-chip global biopharma companies.

With c. 300 employees, Envirotainer operates from regional centres in Stockholm, Frankfurt, Dallas and Singapore, with a portfolio of more than 5,500 leased containers globally. Envirotainer developed and marketed the first container with an active temperature control system in 1995 and since then has significantly invested in technology and its container fleet.

Vinge’s team consisted of partners Christina Kokko and Kristina Ekberg (M&A), Louise Brorsson Salomon and Albert Wållgren (Banking and Finance) together with associates Filip Öhrner, Samra Baytar, Karl Klackenberg, Anna Thoms, Vilhelm Rondahl and Arvid Axelryd (M&A), Linn Adelwald and Agnes Perbo (Banking and Finance), Hedvig Ekdahl, Lisa Hörnqvist and Hayaat Ibrahim (Commercial Agreements), Klara Secher (IP), Sara Strandberg and Sophia Holm (Employment), Johan Cederblad (Environment), Frida Ställborn (Real Estate) and VDR assistant Jessica Öijer.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024